Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Liver Diseases

  Free Subscription


Articles published in J Gastroenterol

Retrieve available abstracts of 63 articles:
HTML format
Text format



Single Articles


    September 2019
  1. PUIGVEHI M, Londono MC, Torras X, Lorente S, et al
    Impact of sustained virological response with DAAs on gastroesophageal varices and Baveno criteria in HCV-cirrhotic patients.
    J Gastroenterol. 2019 Sep 6. pii: 10.1007/s00535-019-01619.
    PubMed     Text format     Abstract available


  2. NAMBA M, Hiramatsu A, Aikata H, Kodama K, et al
    Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis.
    J Gastroenterol. 2019 Sep 4. pii: 10.1007/s00535-019-01623.
    PubMed     Text format     Abstract available


    August 2019
  3. TATEISHI R, Koike K
    Changing etiology of hepatocellular carcinoma.
    J Gastroenterol. 2019 Aug 31. pii: 10.1007/s00535-019-01622.
    PubMed     Text format    


  4. HUO TI, Ho SY
    Evolution of hepatocellular carcinoma: non-B, non-C and beyond.
    J Gastroenterol. 2019 Aug 30. pii: 10.1007/s00535-019-01621.
    PubMed     Text format    


  5. EBADI M, Bhanji RA, Mazurak VC, Montano-Loza AJ, et al
    Sarcopenia in cirrhosis: from pathogenesis to interventions.
    J Gastroenterol. 2019 Aug 7. pii: 10.1007/s00535-019-01605.
    PubMed     Text format     Abstract available


    June 2019
  6. MIZUNO K, Toyoda H, Yasuda S, Tada T, et al
    The course of elderly patients with persistent hepatitis C virus infection without hepatocellular carcinoma.
    J Gastroenterol. 2019 Jun 3. pii: 10.1007/s00535-019-01595.
    PubMed     Text format     Abstract available


    April 2019
  7. MANO Y, Yoshio S, Shoji H, Tomonari S, et al
    Bone morphogenetic protein 4 provides cancer-supportive phenotypes to liver fibroblasts in patients with hepatocellular carcinoma.
    J Gastroenterol. 2019 Apr 2. pii: 10.1007/s00535-019-01579.
    PubMed     Text format     Abstract available


    March 2019
  8. SUMIDA Y, Yoneda M, Okanoue T
    Is the grade of ballooned hepatocytes a significant risk factor for rapid progression of hepatic fibrosis in patients with NAFLD?
    J Gastroenterol. 2019 Mar 26. pii: 10.1007/s00535-019-01573.
    PubMed     Text format    


  9. KAKISAKA K, Suzuki Y, Fujiwara Y, Abe T, et al
    Response to the letter by Sumida et al. regarding our manuscript "Evaluation of ballooned hepatocytes as a risk factor for future progression of fibrosis in patients with non-alcoholic fatty liver disease".
    J Gastroenterol. 2019 Mar 26. pii: 10.1007/s00535-019-01574.
    PubMed     Text format    


  10. NAGANUMA A, Chayama K, Notsumata K, Gane E, et al
    Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection.
    J Gastroenterol. 2019 Mar 13. pii: 10.1007/s00535-019-01569.
    PubMed     Text format     Abstract available


  11. KADO A, Tsutsumi T, Enooku K, Fujinaga H, et al
    Noninvasive diagnostic criteria for nonalcoholic steatohepatitis based on gene expression levels in peripheral blood mononuclear cells.
    J Gastroenterol. 2019 Mar 4. pii: 10.1007/s00535-019-01565.
    PubMed     Text format     Abstract available


    February 2019
  12. TSUSHIMA K, Tsuge M, Hiraga N, Uchida T, et al
    Comparison of intracellular responses between HBV genotype A and C infection in human hepatocyte chimeric mice.
    J Gastroenterol. 2019 Feb 21. pii: 10.1007/s00535-019-01558.
    PubMed     Text format     Abstract available


  13. KOBAYASHI M, Kudo M, Izumi N, Kaneko S, et al
    Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan.
    J Gastroenterol. 2019 Feb 20. pii: 10.1007/s00535-019-01554.
    PubMed     Text format     Abstract available


  14. KIM SK, Takeda H, Takai A, Matsumoto T, et al
    Comprehensive analysis of genetic aberrations linked to tumorigenesis in regenerative nodules of liver cirrhosis.
    J Gastroenterol. 2019 Feb 12. pii: 10.1007/s00535-019-01555.
    PubMed     Text format     Abstract available


  15. KANNO M, Kawaguchi K, Honda M, Horii R, et al
    Serum aldo-keto reductase family 1 member B10 predicts advanced liver fibrosis and fatal complications of nonalcoholic steatohepatitis.
    J Gastroenterol. 2019 Feb 1. pii: 10.1007/s00535-019-01551.
    PubMed     Text format     Abstract available


    January 2019
  16. BRAR G, Tsukamoto H
    Alcoholic and non-alcoholic steatohepatitis: global perspective and emerging science.
    J Gastroenterol. 2019 Jan 14. pii: 10.1007/s00535-018-01542.
    PubMed     Text format     Abstract available


  17. KIMURA K
    Long-awaited treatment for hepatitis C virus decompensated cirrhosis.
    J Gastroenterol. 2019 Jan 1. pii: 10.1007/s00535-018-01538.
    PubMed     Text format    


    November 2018
  18. RAKSAYOT M, Chuaypen N, Khlaiphuengsin A, Pinjaroen N, et al
    Independent and additive effects of PNPLA3 and TM6SF2 polymorphisms on the development of non-B, non-C hepatocellular carcinoma.
    J Gastroenterol. 2018 Nov 30. pii: 10.1007/s00535-018-01533.
    PubMed     Text format     Abstract available


  19. TATEISHI R, Uchino K, Fujiwara N, Takehara T, et al
    A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011-2015 update.
    J Gastroenterol. 2018 Nov 29. pii: 10.1007/s00535-018-1532.
    PubMed     Text format     Abstract available


    October 2018
  20. IIO E, Matsuura K, Shimada N, Atsukawa M, et al
    TLL1 variant associated with development of hepatocellular carcinoma after eradication of hepatitis C virus by interferon-free therapy.
    J Gastroenterol. 2018 Oct 31. pii: 10.1007/s00535-018-1526.
    PubMed     Text format     Abstract available


  21. PARK HE, Lee H, Choi SY, Kwak MS, et al
    Clinical significance of hepatic steatosis according to coronary plaque morphology: assessment using controlled attenuation parameter.
    J Gastroenterol. 2018 Oct 4. pii: 10.1007/s00535-018-1516.
    PubMed     Text format     Abstract available


    September 2018
  22. TAKEHARA T, Sakamoto N, Nishiguchi S, Ikeda F, et al
    Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial.
    J Gastroenterol. 2018 Sep 10. pii: 10.1007/s00535-018-1503.
    PubMed     Text format     Abstract available


    July 2018
  23. SHIMA T, Uto H, Ueki K, Kohgo Y, et al
    Hepatocellular carcinoma as a leading cause of cancer-related deaths in Japanese type 2 diabetes mellitus patients.
    J Gastroenterol. 2018 Jul 13. pii: 10.1007/s00535-018-1494.
    PubMed     Text format     Abstract available


    June 2018
  24. HUANG R, Wang J, Xia J, Hao Y, et al
    Potential clinical application of strain elastography in chronic liver diseases.
    J Gastroenterol. 2018;53:795-796.
    PubMed     Text format    


  25. TAJIRI K, Kawai K, Sugiyama T
    Reply to "Letter to Editor submitted by Rui Huang et al. entitled potential clinical application of strain elastography in chronic liver diseases".
    J Gastroenterol. 2018;53:797-798.
    PubMed     Text format    


    May 2018
  26. ENOOKU K, Kondo M, Fujiwara N, Sasako T, et al
    Hepatic IRS1 and ss-catenin expression is associated with histological progression and overt diabetes emergence in NAFLD patients.
    J Gastroenterol. 2018 May 10. pii: 10.1007/s00535-018-1472.
    PubMed     Text format     Abstract available


  27. ORIMO T, Kamiyama T, Mitsuhashi T, Kamachi H, et al
    Impact of tumor localization on the outcomes of surgery for an intrahepatic cholangiocarcinoma.
    J Gastroenterol. 2018 May 2. pii: 10.1007/s00535-018-1469.
    PubMed     Text format     Abstract available


    April 2018
  28. KAKISAKA K, Suzuki Y, Fujiwara Y, Abe T, et al
    Evaluation of ballooned hepatocytes as a risk factor for future progression of fibrosis in patients with non-alcoholic fatty liver disease.
    J Gastroenterol. 2018 Apr 21. pii: 10.1007/s00535-018-1468.
    PubMed     Text format     Abstract available


  29. YAGI M, Tanaka A, Namisaki T, Takahashi A, et al
    Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study.
    J Gastroenterol. 2018 Apr 16. pii: 10.1007/s00535-018-1465.
    PubMed     Text format     Abstract available


    February 2018
  30. YONEDA M, Imajo K, Takahashi H, Ogawa Y, et al
    Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods.
    J Gastroenterol. 2018;53:181-196.
    PubMed     Text format     Abstract available


  31. NAKAHARA T, Hyogo H, Ono A, Nagaoki Y, et al
    Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease.
    J Gastroenterol. 2018;53:269-280.
    PubMed     Text format     Abstract available


    December 2017
  32. SHINKAI N, Nojima M, Iio E, Matsunami K, et al
    High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues.
    J Gastroenterol. 2017 Dec 29. pii: 10.1007/s00535-017-1424.
    PubMed     Text format     Abstract available


  33. VITALE G, Gitto S, Raimondi F, Mattiaccio A, et al
    Cryptogenic cholestasis in young and adults: ATP8B1, ABCB11, ABCB4, and TJP2 gene variants analysis by high-throughput sequencing.
    J Gastroenterol. 2017 Dec 13. pii: 10.1007/s00535-017-1423.
    PubMed     Text format     Abstract available


    November 2017
  34. SUZUKI Y, Mori T, Yokoyama M, Kim S, et al
    A proposed severity classification system for hepatolithiasis based on an analysis of prognostic factors in a Japanese patient cohort.
    J Gastroenterol. 2017 Nov 8. doi: 10.1007/s00535-017-1410.
    PubMed     Text format     Abstract available


  35. SHANG L, Hosseini M, Liu X, Kisseleva T, et al
    Human hepatic stellate cell isolation and characterization.
    J Gastroenterol. 2017 Nov 1. doi: 10.1007/s00535-017-1404.
    PubMed     Text format     Abstract available


    October 2017
  36. KOYAMA N, Yamazaki T, Kanetsuki Y, Hirota J, et al
    Activation of apoptosis inhibitor of macrophage is a sensitive diagnostic marker for NASH-associated hepatocellular carcinoma.
    J Gastroenterol. 2017 Oct 30. doi: 10.1007/s00535-017-1398.
    PubMed     Text format     Abstract available


  37. NAKAO M, Nakayama N, Uchida Y, Tomiya T, et al
    Nationwide survey for acute liver failure and late-onset hepatic failure in Japan.
    J Gastroenterol. 2017 Oct 13. doi: 10.1007/s00535-017-1394.
    PubMed     Text format     Abstract available


  38. WANG W, Pan Q, Fuhler GM, Smits R, et al
    Erratum to: Action and function of Wnt/beta-catenin signaling in the progression from chronic hepatitis C to hepatocellular carcinoma.
    J Gastroenterol. 2017 Oct 11. doi: 10.1007/s00535-017-1392.
    PubMed     Text format     Abstract available


    September 2017
  39. CHAYAMA K, Suzuki F, Karino Y, Kawakami Y, et al
    Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis.
    J Gastroenterol. 2017 Sep 25. doi: 10.1007/s00535-017-1391.
    PubMed     Text format     Abstract available


  40. IMPERATORE N, Tortora R, Testa A, Gerbino N, et al
    Erratum to: Proton pump inhibitors as risk factor for metabolic syndrome and hepatic steatosis in coeliac disease patients on gluten-free diet.
    J Gastroenterol. 2017 Sep 19. doi: 10.1007/s00535-017-1393.
    PubMed     Text format     Abstract available


    August 2017
  41. KAWAGUCHI K, Honda M, Ohta H, Terashima T, et al
    Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts hepatocellular carcinoma incidence and recurrence in nucleos(t)ide analogue therapy for chronic hepatitis B.
    J Gastroenterol. 2017 Aug 28. doi: 10.1007/s00535-017-1386.
    PubMed     Text format     Abstract available


  42. IMPERATORE N, Tortora R, Anna T, Gerbino N, et al
    Proton pump inhibitors as risk factor for metabolic syndrome and hepatic steatosis in coeliac disease patients on gluten-free diet.
    J Gastroenterol. 2017 Aug 19. doi: 10.1007/s00535-017-1381.
    PubMed     Text format     Abstract available


  43. KOBAYASHI K, Maruyama H, Kiyono S, Ogasawara S, et al
    Application of transcutaneous ultrasonography for the diagnosis of muscle mass loss in patients with liver cirrhosis.
    J Gastroenterol. 2017 Aug 18. doi: 10.1007/s00535-017-1378.
    PubMed     Text format     Abstract available


  44. SHIDA T, Akiyama K, Oh S, Sawai A, et al
    Skeletal muscle mass to visceral fat area ratio is an important determinant affecting hepatic conditions of non-alcoholic fatty liver disease.
    J Gastroenterol. 2017 Aug 8. doi: 10.1007/s00535-017-1377.
    PubMed     Text format     Abstract available


  45. IKEDA M, Kudo M, Aikata H, Nagamatsu H, et al
    Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial.
    J Gastroenterol. 2017 Aug 1. doi: 10.1007/s00535-017-1374.
    PubMed     Text format     Abstract available


    July 2017
  46. KITAJIMA Y, Takahashi H, Akiyama T, Murayama K, et al
    Supplementation with branched-chain amino acids ameliorates hypoalbuminemia, prevents sarcopenia, and reduces fat accumulation in the skeletal muscles of patients with liver cirrhosis.
    J Gastroenterol. 2017 Jul 24. doi: 10.1007/s00535-017-1370.
    PubMed     Text format     Abstract available


  47. SEKO Y, Sumida Y, Sasaki K, Itoh Y, et al
    Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials.
    J Gastroenterol. 2017 Jul 1. doi: 10.1007/s00535-017-1364.
    PubMed     Text format     Abstract available


    June 2017
  48. HIRAMINE Y, Uojima H, Nakanishi H, Hiramatsu A, et al
    Response criteria of tolvaptan for the treatment of hepatic edema.
    J Gastroenterol. 2017 Jun 29. doi: 10.1007/s00535-017-1366.
    PubMed     Text format     Abstract available


  49. OKANOUE T, Ebise H, Kai T, Mizuno M, et al
    A simple scoring system using type IV collagen 7S and aspartate aminotransferase for diagnosing nonalcoholic steatohepatitis and related fibrosis.
    J Gastroenterol. 2017 Jun 6. doi: 10.1007/s00535-017-1355.
    PubMed     Text format     Abstract available


  50. TAJIRI K, Kawai K, Sugiyama T
    Strain elastography for assessment of liver fibrosis and prognosis in patients with chronic liver diseases.
    J Gastroenterol. 2017;52:724-733.
    PubMed     Text format     Abstract available


    May 2017
  51. MASUDA K, Ono A, Aikata H, Kawaoka T, et al
    Erratum to: Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy.
    J Gastroenterol. 2017 May 29. doi: 10.1007/s00535-017-1352.
    PubMed     Text format    


  52. OBA A, Kudo A, Akahoshi K, Kishino M, et al
    A simple morphological classification to estimate the malignant potential of pancreatic neuroendocrine tumors.
    J Gastroenterol. 2017 May 9. doi: 10.1007/s00535-017-1349.
    PubMed     Text format     Abstract available


  53. MASUDA K, Ono A, Aikata H, Kawaoka T, et al
    Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy.
    J Gastroenterol. 2017 May 4. doi: 10.1007/s00535-017-1348.
    PubMed     Text format     Abstract available


    April 2017
  54. KIM TJ, Sinn DH, Min YW, Son HJ, et al
    A cohort study on Helicobacter pylori infection associated with nonalcoholic fatty liver disease.
    J Gastroenterol. 2017 Apr 5. doi: 10.1007/s00535-017-1337.
    PubMed     Text format     Abstract available


  55. FLOREANI A, Tanaka A, Bowlus C, Gershwin ME, et al
    Geoepidemiology and changing mortality in primary biliary cholangitis.
    J Gastroenterol. 2017 Apr 1. doi: 10.1007/s00535-017-1333.
    PubMed     Text format     Abstract available


    March 2017
  56. CAI X, Hayashi S, Fang C, Hao S, et al
    Pu'erh tea extract-mediated protection against hepatosteatosis and insulin resistance in mice with diet-induced obesity is associated with the induction of de novo lipogenesis in visceral adipose tissue.
    J Gastroenterol. 2017 Mar 31. doi: 10.1007/s00535-017-1332.
    PubMed     Text format     Abstract available


  57. ZHANG AY, Lai CL, Huang FY, Seto WK, et al
    Deep sequencing analysis of quasispecies in the HBV pre-S region and its association with hepatocellular carcinoma.
    J Gastroenterol. 2017 Mar 28. doi: 10.1007/s00535-017-1334.
    PubMed     Text format     Abstract available


  58. KISHIDA Y, Okubo H, Ohno H, Oki K, et al
    Effect of miglitol on the suppression of nonalcoholic steatohepatitis development and improvement of the gut environment in a rodent model.
    J Gastroenterol. 2017 Mar 27. doi: 10.1007/s00535-017-1331.
    PubMed     Text format     Abstract available


  59. HASEBE T, Tanaka H, Sawada K, Nakajima S, et al
    Bone morphogenetic protein-binding endothelial regulator of liver sinusoidal endothelial cells induces iron overload in a fatty liver mouse model.
    J Gastroenterol. 2017;52:341-351.
    PubMed     Text format     Abstract available


    February 2017
  60. SETO WK, Yuen MF
    Nonalcoholic fatty liver disease in Asia: emerging perspectives.
    J Gastroenterol. 2017;52:164-174.
    PubMed     Text format     Abstract available


  61. MORIO R, Hyogo H, Hatooka M, Morio K, et al
    The risk of transient postprandial oxyhypoglycemia in nonalcoholic fatty liver disease.
    J Gastroenterol. 2017;52:253-262.
    PubMed     Text format     Abstract available


  62. MIYAKE T, Hirooka M, Yoshida O, Furukawa S, et al
    Differences in the risk of fatty liver for onset of impaired fasting glucose according to baseline plasma glucose levels.
    J Gastroenterol. 2017;52:237-244.
    PubMed     Text format     Abstract available


    June 2016
  63. YAMADA N, Sanada Y, Tashiro M, Hirata Y, et al
    Serum Mac-2 binding protein glycosylation isomer predicts grade F4 liver fibrosis in patients with biliary atresia.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: